Poolbeg Pharma's £4m raise shows ambition

Raising fresh capital is a familiar rhythm for early-stage biotech companies. For Poolbeg Pharma PLC (AIM:POLB), the question is not simply whether it can fund its ambitions, but whether its pipeline can justify them. Expert opinion is broadly optimistic on this point.

The company has announced a £4.1 million equity raise, priced at 2.5p per share, a 12% discount to the market price, to finance the next stage of development for its two lead assets: POLB 001, targeting cancer immunotherapy induced cytokine release syndrome (CRS), and an oral glucagon like peptide 1 (GLP-1) receptor agonist designed for obesity treatment.

Tackling a major cancer therapy bottleneck

Cytokine release syndrome is a serious complication arising in patients undergoing CAR-T or bispecific antibody therapies, where an overactive immune response can lead to high fevers, low blood pressure and organ failure.

According to analysts at Shore Capital, CRS affects over 70% of patients receiving such therapies and has been a major limiting factor in their wider deployment.

POLB 001 is designed as an oral preventative treatment, a notable shift from existing drugs like Roche’s injectable Actemra, which is approved for treating CRS after symptoms appear.

Broker Cavendish notes that Poolbeg’s preclinical and human challenge data already show clear suppression of key inflammatory cytokines.

If Phase 2a data confirm this, the company could be first to market with an oral CRS prophylactic, a development that Cavendish estimates could unlock a market opportunity exceeding $10 billion, initially in blood cancers and potentially in solid tumours too.

The Phase 2a trial is expected to begin in the second half of this year. Big Pharma is reportedly providing the bispecific antibody therapy used in the trial at no cost, a move analysts at both Shore and Cavendish interpret as early validation of POLB 001’s commercial promise.

Seeking a slice of the weight loss boom

Poolbeg’s second programme enters another multibillion-dollar market: obesity. With injectable GLP-1 agonists such as Ozempic and Wegovy driving record revenues for Novo Nordisk and Eli Lilly, the race is now on to develop effective oral formulations that improve patient convenience and compliance.

Poolbeg’s answer is a proprietary microencapsulation technology licensed from AnaBio. A proof-of-concept study will begin this year at the University of Ulster, with topline data due in the first half of 2026.

ShoreCap argues that the approach could provide a differentiated product in a market forecast to reach $150 billion by the early 2030s.

Cash, catalysts and credibility

Cavendish notes Poolbeg ended the first quarter of 2025 with £6.2 million in cash. The current raise, assuming shareholder approval, will extend the company’s runway into 2027.

That should be enough to reach multiple clinical milestones and, ideally, deliver the data needed to secure commercial partners.

Importantly, the raise also comes with insider backing. Executive chair Cathal Friel has committed to invest £100,000, providing a measure of confidence in the company’s direction.

Execution

Still, investors should keep their eyes on execution. While both POLB 001 and the GLP-1 asset are tackling real clinical problems with significant market potential, they remain pre-revenue and subject to trial risk.

Poolbeg’s ability to translate promise into partnerships will be the key driver of any future valuation shift.

Cavendish maintains a 19p target on the shares, implying significant upside from the current 2.9p.

But for that to materialise, the next 12 to 18 months will need to deliver more than just well-funded plans. They will need hard data.